Why is pancreatic cancer so hard to detect early?

It shows almost no early symptoms, and conventional CT misses roughly 40% of lesions under 2cm — the objective limit of human visual review.

How does PANCREASaver work?

A CNN + radiomics dual-engine analyzes contrast-enhanced abdominal CT images, flags suspicious lesions in real time, and triggers a PACS alert for the reading radiologist.

Do I need a separate “pancreas AI” CT scan?

No. The system analyzes existing abdominal CT images. Whether a scan is appropriate should be discussed with your physician.

Does an AI flag mean I have cancer?

No. An AI flag is a high-risk reminder that tells the physician to take another look. The final diagnosis is always made by the physician.

Why does early detection matter?

When found and treated at under 2cm, five-year survival can reach about 80% — compared with under 10% for late-stage disease.

Who should consider screening?

High-risk groups — family history, new-onset diabetes, age 60+, long-term smoking — should discuss screening with their physician.

Where is the product available?

Deployed at multiple medical institutions and health checkup centers in Taiwan.

PANCREASaver® — AI Early Detection for Pancreatic Cancer

The product

PANCREASaver^® — AI early detection for pancreatic cancer

An AI medical device that reads contrast-enhanced abdominal CT scans the moment they finish — marking sub-2cm pancreatic lesions the human eye can miss. FDA Breakthrough-designated. TFDA-licensed. Live in hospitals today.

PANCREASaver AI marking a sub-2cm pancreatic lesion on abdominal CT

Real CT · PANCREASaver^® AI overlay — sub-2cm lesion auto-marked

The same scan, without AI

⚡ Fully automated

Analysis starts the moment the scan completes — no clicks, no extra steps for the reading radiologist.

🎯 92.1% sub-2cm sensitivity

Catches the small lesions that determine outcomes — nationwide multi-center AUC 0.95.

🔗 Seamless PACS integration

DICOM-native and vendor-neutral — fits your existing PACS with zero workflow change.

Explore the product Request a demo

92.1%

Sensitivity (<2cm tumors)

0.95

Multi-center AUC

2000+

Cases interpreted (incl. clinical validation)

Patents (TW & US)

Seamless PACS integration

Built for the way you already work

Vendor-neutral, DICOM-native, and deployed in weeks — PANCREASaver® fits your existing PACS without changing a single step of your radiology workflow.

🔗 Works with your existing PACS 🏥 Vendor-neutral ⚡ No workflow change 🗓️ Live in ~4 weeks

See the integration in the product overview ↗

All-in-one evidence

From product to certification, all in one place.

Six themes covering the full picture of PANCREASaver® — swipe to explore.

Product

The world's first pancreatic cancer CT AI detection

A fully automated end-to-end system: analyzes CT scans as they finish, flags suspicious lesions within 5 minutes, integrated with hospital PACS/RIS.

Learn more

Clinical Data

Nationwide real-world validation of 1,473 cases, AUC 0.95

89.7% sensitivity, 92.8% specificity; 92.1% sensitivity for tumors <2cm — published in Radiology and The Lancet Digital Health.

View clinical data

Publications

5 international papers, every line verifiable.

Real papers in The Lancet Digital Health, Radiology, BMC Cancer and more — bilingual topics, real abstracts and PubMed links.

Visit the publication hall

IP Portfolio

10 patents in Taiwan & US, building a technology moat.

System-level and method-level claims covering medical imaging analysis and ML-based pancreatic cancer detection — US medical AI patents are exceptionally hard to obtain.

View IP portfolio

Regulatory

TFDA clearance, FDA Breakthrough designation

TFDA license No. 007946 (2023), FDA Breakthrough Device Designation (2022), 510(k) application submitted (2026.7).

See certification journey

Deployment

From contract to go-live, deployed in 4 weeks.

Medical centers, regional hospitals and health centers — 2,000+ reading sessions. Data stays on-premise, SaaS subscription, continuous model updates.

View deployment plans

Why early detection matters

Pancreatic cancer hides. Until it can’t.

The size of the tumor when it is found is one of the strongest predictors of outcome. This is the problem PANCREASaver® was built to change.

<10% Overall five-year survival — mostly because pancreatic cancer is usually found after it has already spread.

<2cm The early window where treatment options are broadest — and where PANCREASaver® achieves 92.1% sensitivity.

Found late = few options By the time symptoms appear, the tumor has often spread. AI-assisted review of routine CT studies is designed to find the lesion before it becomes a late-stage diagnosis. Why screening matters ↗

Figures as published in peer-reviewed literature and PanCAD.ai’s clinical validation. See the evidence center for sources.

Regulatory & trust

Approved. Breakthrough. Verified.

Every claim on this website is backed by an issuing authority, a publication, or a verifiable record.

TFDA LicensedTaiwan · 衛部醫器製字第007946號

FDA BreakthroughU.S. FDA · Designated

🛂

510(k) SubmittedJuly 2026 · Under review

🧩

10 Patents4 U.S. · 6 Taiwan

📄

5 PublicationsLancet Digital Health · Radiology

🏆

9 AwardsRSNA Margulis 2023 · first for Taiwan

Full regulatory status ↗

Designed for You

Patient, physician, or health center

Three doors, three journeys. PANCREASaver® is one care chain — from the screening table to the bedside.

🏠

Patients & Families

Learn about early detection, the care journey, and the hope it brings. From “what do I do now?” to “it can be found this early.”

Enter Patient Journey

🩺

For Clinicians

The interactive evidence hall: AUC 0.95, 92.1% sensitivity, regulatory approvals, and integration workflow — decision-ready in 30 seconds.

See Evidence

🧬

Health Centers

Add pancreatic cancer AI screening to your checkup packages: workflow integration, radiology collaboration, 2,000+ real-world cases.

Explore Screening

Patient First

An ordinary-looking day, until AI spotted a hidden risk and changed everything

One morning, one checkup, one small circle — and a family that kept its tomorrow. Early detection changes everything.

06:00 AM · Dawn

A beautiful day to be out

It was his favorite kind of morning. Sunlight over the riverbank. He felt fine — he didn't know anything yet.

10:30 AM · Checkup

AI circled a small mark

In a routine abdominal CT, AI circled a 1.2cm tumor — so small the human eye almost missed it.

07:00 PM · Dinner

The whole family at the table

Because it was found early, options remained. The family sat together, laughing as always.

See the full day

The Care Journey

From screening to survivorship, every step guarded

Scroll through five stations — the complete path PANCREASaver® walks with patients and physicians.

Screening: why check regularly

Early pancreatic cancer is nearly silent. By the time symptoms appear, it is often no longer early. For high-risk groups, regular imaging screening is the only way to buy time.

Regular Checkups ｜ High-Risk Groups ｜ Health Centers

Detection: AI sees it at 1.2cm

After an abdominal CT, AI circles a 1.2cm tumor — 92.1% sensitivity under 2cm. What can be seen can be treated.

Interactive CT ｜ 92.1% Sensitivity

Diagnosis: the physician's double check

AI findings go to radiologists for review, then specialists confirm the diagnosis. AI doesn't replace physicians — it lets them see earlier and more precisely.

Radiologists ｜ Reading ｜ Double Confirmation

Treatment: early means options

A 1cm tumor and a metastasized one have completely different paths. Early detection means more surgical options and better odds.

Surgical Options ｜ Survival ｜ Multidisciplinary Team

Survivorship: live well, with family

After treatment comes regular follow-up. We protect more than a scan — we protect a home. Every ordinary day deserves protection.

Follow-up ｜ Quality of Life ｜ Live Fully

Milestones

From research bench to bedside

2016Research begins at National Taiwan University

Prof. Wang’s team launches early pancreatic cancer imaging AI research with Prof. Liao’s clinical team at NTU Hospital.

2019Multi-center clinical validation

Nationwide multi-center validation begins, building the dataset behind the AUC 0.95 national performance.

2023RSNA Margulis Award · FDA Breakthrough

PANCREASaver® wins the RSNA Margulis Award — the first for Taiwan — and receives U.S. FDA Breakthrough Device Designation.

2026TFDA license · 510(k) submitted

Licensed by Taiwan’s TFDA (衛部醫器製字第007946號); 510(k) submitted to the U.S. FDA in July 2026.

30-Second Awareness

Are you or a loved one at higher risk?

Five simple questions to raise awareness — not a diagnosis, but the first step to “talk to your doctor.”

Start the 30-Second Check

1Age 60 or above

2Family history of pancreatic cancer

3Long-term smoking or diabetes

4Recurrent pancreatitis

News

Every step, good news

2026.08

2026 Storm Media AI Healthcare Innovation Awards (AIHIA) — PANCREASaver® recognized ↗

Storm Media's AI Healthcare Innovation Awards recognized PANCREASaver® for helping overcome the early-detection bottleneck in pancreatic cancer.